Sunrest Lifescience IPO Date, Review, Price, Allotment Details

Sunrest Lifescience IPO product range encompasses a variety of pharmaceutical forms, including capsules, tablets, syrups, ointments, gels, mouthwashes, solutions, suspensions, dry powders, and toothpaste. Their diverse product portfolio covers a wide spectrum of medications, including antibacterial, antidiarrheal, antifungal, antidiabetic, dental care, antiprotozoal, antihistamine, antihypertensive, cosmetic, antiparasitic, multivitamin, multimineral, nutraceutical, and anti-inflammatory drugs. The company holds 18 registered trademarks for 32 products, indicating their commitment to quality and brand recognition.

Sunrest Lifescience distributes its products to stockists and super stockists, making them readily available at chemist shops, dispensaries, hospitals, and other healthcare facilities.

Sunrest Lifescience IPO Timeline

Sunrest Lifescience IPO opens on November 7, 2023, and closes on November 9, 2023.

IPO Open DateTuesday, November 7, 2023
IPO Close DateThursday, November 9, 2023
Basis of AllotmentWednesday, November 15, 2023
Initiation of RefundsThursday, November 16, 2023
Credit of Shares to DematFriday, November 17, 2023
Listing DateMonday, November 20, 2023
Cut-off time for UPI mandate confirmation5 PM on November 9, 2023

Sunrest Lifescience IPO Lot Size

Investors can bid for a minimum of 1600 shares and in multiples thereof. The below table depicts the minimum and maximum investment by retail investors and HNI in terms of shares and amount.

Retail (Min)11600₹134,400
Retail (Max)11600₹134,400
HNI (Min)23,200₹268,800

About the Issue

Sunrest Lifescience IPO is set to raise Rs 10.85 crores through a fixed price issue. This IPO comprises entirely fresh shares, totaling 12.91 lakh shares.

The subscription period for Sunrest Lifescience IPO will be open from November 7, 2023, to November 9, 2023. The allotment of shares is expected to be finalized by Wednesday, November 15, 2023. Sunrest Lifescience IPO is set to list on the NSE SME platform, with a tentative listing date of Monday, November 20, 2023.

The price per share in the Sunrest Lifescience IPO is set at ₹84. Retail investors can apply for a minimum of 1600 shares, amounting to an investment of ₹134,400. High Net Worth Individuals (HNI) can apply for a minimum of 3,200 shares, which corresponds to an investment of ₹268,800.

Sunrest Lifescience Limited Financials

Sunrest Lifescience Limited’s revenue decreased by -8.32% and profit after tax (PAT) rose by 162.91% between the financial year ending with March 31, 2023 and March 31, 2022.

Period Ended30 Jun 202331 Mar 202331 Mar 202231 Mar 2021
Profit After Tax75.08204.3177.7116.55
Net Worth386.60311.52107.2029.49
Reserves and Surplus86.6011.52106.2028.49
Total Borrowing347.32214.32323.83231.55

Objects of the Issue:

  • Meeting Working Capital Requirements
  • General Corporate Purpose
  • Meeting Public Issue Expenses

Sunrest Lifescience IPO Registrar

Skyline Financial Services Private Ltd
Phone: 02228511022
Email: Virenr@Skylinerta.Com

Company Address

Sunrest Lifescience Limited
FF-41, Ajay Tenament-6,
Near Canal Near Ritanagar, Bus Stand Vastral Road,
Phone: +91-079 – 29918245

Sunrest Lifescience IPO FAQs

What is Sunrest Lifescience IPO?

Sunrest Lifescience IPO is an NSE SME IPO. They are going to raise ₹10.85 Crores via IPO. The issue is priced at ₹84 per equity share. The IPO is to be listed on NSE.

When Sunrest Lifescience IPO will open?

The IPO is to open on November 7, 2023 for QIB, NII, and Retail Investors.

What is Sunrest Lifescience IPO Investors Portion?

The investors’ portion for NII is 50%, and Retail is 50%.

How to Apply the Sunrest Lifescience IPO through Zerodha?

Steps to apply in Sunrest Lifescience IPO through Zerodha

  1. Visit the Zerodha website and login to Console.
  2. Go to Portfolio and click the IPOs link.
  3. Go to the ‘Sunrest Lifescience IPO’ row and click the ‘Bid’ button.
  4. Enter your UPI ID, Quantity, and Price.
  5. ‘Submit’ IPO application form.
  6. Visit the UPI App (net banking or BHIM) to approve the mandate.

Leave a comment